2022 15 best-selling anti-cancer drugs: the top three I-O products into Top,China Mingxuan

Medical news network February 28th recently, FiercePharma released the 2022 15 best-selling drugs forecast, is expected to 2022, the 15 best-selling anticancer drugs will create nearly $90 billion in sales, gross IMS quintiles statistics in 2014 the United States pharmaceutical market 1/4.

In this list, 3 PD-1/PD-L1 inhibitors belonging to the tumor immunotherapy (I-O) therapy ranked the top 6. However, there is a certain controversy in the pricing of such drugs, and now, the global drug pricing are strictly regulated by regulators and the payment of a certain degree of repression.

The big difference between the new best-selling anti-cancer drug list and the 3 year old version shows the rapid pace of development of the anti-cancer drug industry. For example, Takeda Pharmaceutical (Takeda) melanoma drug Velcade (Velcade) and Johnson (J&J) of the oral anti prostate cancer drug abiraterone acetate (Zytiga) have disappeared in 2022 the most popular anticancer drug list, two are new drugs and generic drugs will encounter the threat.

Despite the rapid development of cancer immunotherapy, 9 of the top 15 best-selling anti-cancer drugs in 2022 were monoclonal antibodies, of which only 3 were from Roche (Roche). This is also the first few drugs will face similar challenges to the biological medicine monoclonal antibody drugs in the next few years, but its brand strength is still to remain an important position in the market.

1, Revlimid

Lenalidomide (Revlimid) has been listed for 10 years has been based medicine (Celgene) is an important marketing power, the drug is a new medium product is the most important section of the medicine for treating blood disorders, the company in the sector expected 2020 annual sales of more than $15 billion, and lenalidomide sales in 2022 is expected to double.

The new medicine base had to spend $1 billion to expand the lenalidomide for non Hodgkin lymphoma (NHL) subtypes and maintenance therapy in diffuse large B cell lymphoma phase III clinical indications, but failed, after the drug treatment trials continue to receive follicular lymphoma. The new foundation is still confident of the importance of lenalidomide, which is believed to be an important driving force in the 2020 and beyond.

2, Opdivo

In 2014, Japan's Opdivo is the first approved for lung cancer effective PD-1 inhibitors by Merck (Merck) PD-1 inhibitor Keytruda developed than those in the early 3 months in the United states.

In 2022, Opdivo will gain a leading position in the next generation of cancer immunotherapy, but its sales are expected to be reduced by the impact of the failure of the first line of non-small cell lung cancer (CheckMate-026) trial. This makes its pace of market development is still subject to Keytruda, as well as Roche's Tecentriq. According to the analysis, if the test is not falter, even created Opdivo in 2022 sales of $14 billion 600 million.

3, Imbruvica

Bruton tyrosine kinase inhibitor Imbruvica in early 2013 after the listing soon broke through the heavy drug sales start line, now the drug in chronic lymphocytic leukemia (CLL) in a leading position in the second-line treatment market.

In March last year, Imbruvica received FDA approval for the first-line treatment of CLL, more long-term treatment for patients who need to bring the opportunity to recover early. In addition to the potential for new indications such as non Hodgkin's lymphoma, pancreatic cancer and acute leukemia and other solid solid tumors, Imbruvica sales in 2022 is expected to be highly possible. But in the next few years, the drug may face some fierce competition, the new base medicine Revlimid has shown strong indications for the treatment of lymphoma indications.

4, Keytruda

In September 2014 by the FDA Keytruda is the first authorized accelerated approval in PD-1/PD-L1 inhibitor approved us, but now the sales performance has lagged behind the Opdivo, both have a direct competitive relationship in the treatment of non-small cell lung cancer as second-line treatment for head and neck cancer and melanoma, the. With Keytruda's first line of treatment for non-small cell lung cancer, FDA was approved, and Opdivo failed to meet the primary endpoint of the treatment in the trial, which also has an advantage in the race.

At present, the main reason for the lack of Keytruda in the second-line treatment of non-small cell lung cancer is that it must rely on the PD-L1 test, which applies to all patients with Opdivo.

5, Ibrance

Ibrance is the first drug to be listed in the CDK 4/6 inhibitor. In February 2015, he entered the stage of history with a combination of letrozole, a hormone receptor positive (HR+) human epidermal growth factor negative (HER2-) and a spread of breast cancer.

The drug in 2016 did not appear any decline in sales in the first half of the year has achieved a very impressive sales of $950 million. The sales growth also benefited from the second approved indications, and AstraZeneca (AstraZeneca) Faslodex (fulvestrant) combined therapy for the treatment of the use of hormone therapy after the illness is still deteriorating patients.

However, brance's potential competitors will soon follow the pace of its listing, such as ribociclib (Novartis) will be approved by FDA's priority review path.

6, Tecentriq

For Roche's Tecentriq PD-1/PD-L1 inhibitor in the market ranked third, than the Keytruda and Opdivo in the evening, about a year, but soon the treatment of bladder cancer in the United States market occupy a space for one person, $19 million in sales achieved only in a few weeks, then got lung cancer indications approved. Tecentriq bladder cancer indications approved the earliest, while expanding its market share in the treatment of lung cancer, but also to prepare a new indication for colorectal cancer.

Roche as a global leader in the field of anti-cancer drugs, Tecentriq will rely on its long-term reputation and good reputation in the market continue to maintain substantial growth momentum. But Roche also needs to speed up the pace of testing and approval of its more indications, because many of the company's heavy drugs have begun to face the competition of biological drugs.

7, Darzalex

Shoulder the task of expanding the market share of Johnson, multiple sclerosis drugs Darzalex officially listed in 2015. The four line for the drug treatment, in the treatment sequence, which is located in the new Pomalyst based medicine (pomalidomide) and An Jin (Amgen) Kyprolis (carfilzomib), Johnson is currently trying to treat the drug order in advance.

In 2016, Darzalex phase III clinical data released by the American Society of Clinical Oncology, combined with the use of the drug and Takeda pharmaceutical Velcade as second-line therapy can effectively reduce mortality or worsening of cancer 61%.

8, Perjeta

Perjeta, which was launched in 2012, became the fastest selling new drug in the country due to the availability of early indications for HER2 positive breast cancer and the expansion of early treatment for other cancers. In 2022, Perjeta sales forecasts for more than $4 billion 730 million, due to similar biological drug sales decreased $2 billion 800 million competition heavy Roche breast cancer drug Herceptin (Herceptin).

In 2013, Perjeta became the first approved by the FDA before the surgery of breast cancer treatment, significantly expanding patient population can be used. The drug Herceptin and docetaxel chemotherapy or combined therapy to reduce breast tumor size, the FDA approved the first mainly for tumor shrinkage and non cancer drug improved survival.

9, Xtandi

In 2016, Pfizer (Pfizer) spent $14 billion acquisition of Medivation has received great attention, through this transaction, Pfizer has been the rapid growth of prostate cancer drug Xtandi.

Although in the last year, Johnson heavy prostate cancer drug abiraterone is gaining momentum (Zytiga) to $more than 2 billion 200 million in sales in the Bean complex Lu amine but some of the advantages of a stroke above, is helping to gradually shorten the distance. Enzalutamide can be used alone, and combined with the steroidprednisone abbitt Dragon (steroid prednisone) to balance the use of side effects. According to the requirements of FDA, received abiraterone patients also need regular attention in liver enzyme levels, toxicity risk alert.

However, in the United States is facing price pressure. CVS has been able to remove the drug from the 2017 drug list, based on cost reasons, and could face competition from Provenge, Xifigo and Vaillant (Valeant) prostate cancer drugs.

10, Avastin

Vascular endothelial growth factor (VEGF) on the antibody targeting drug A Vastin (Avastin) is the current Roche heavy drug in the second main sales in 2004 for the first time, which is approved for the treatment of colorectal cancer, then continue to add new indications, recently won European approval and Tarceva (Tarceva) combined with the epidermal growth factor receptor (EGFR-positive) positive non-small cell lung cancer. In 2017, the joint therapy trial with Tecentriq will be launched, and it is likely that the future will be approved.

In 2015, sales rose by 9%, but it has begun to be influenced by the competition for bio based drugs listed in emerging markets. In addition, Amgen and AI Erjian (Allergan) last year announced its biological drug like worldwide to submit the listing application plan; India Biocon and Meiland (Mylan) has a similar biological medicine in the review stage in europe.

11, Herceptin

In 1998, Roche's Hessaitin (Herceptin) market, a revolutionary treatment for the treatment of HER2 positive breast cancer patients who have a bleak prospect of survival. Now, the disease treatment of Herceptin still occupy 90% market share, but because of its European patent has expired on 2014, the United States patent will only keep until 2019, it has begun to encounter challenges from similar biological medicine.

A similar biological medicine version of Canmab and Biocon have been listed mylan Herceptin in India, analysts believe the drug will be available in Europe in 2017, 2018 in the United States; Celltrion's biological drug like Herzuma has listed in South korea. However, Roche's chief operating officer Daniel O Day in the two quarter of 2016 said in a conference call that Herceptin in the biological invasion of the similar drug market still maintain a certain growth.

12, Gazyva

In the face of heavy blood cancer drug rituximab (Rituxan) in similar biological drug challenge faced in 2017, Roche's blood cancer treatment sector will be more dependent on the B cell malignant tumor Gazyya, the drug is an upgraded version of rituximab. Gazyya was approved in 2013 for the treatment of chronic lymphocytic leukemia (CLL), which was difficult to treat early in the first place, and the sales volume was weak, but there was a significant improvement in follicular lymphoma indications.

In the last year of the American Society of Hematology annual meeting results of phase III clinical trials published show that Gazyva combined with chemotherapy has better curative effect in the treatment of Hua Bimei follicular lymphoma at. In addition, Gazyva on acute myeloid leukemia, multiple sclerosis and mesothelioma, and Roche and Ai Bowei cooperation in the development of the combination of Venclexta test for treatment of chronic lymphocytic leukemia have made some progress.

13, Jakafi

In fact, Jakafi can enter the top 15 list a little surprise. Last year, after the drug failed to meet the prostate and colorectal cancer trial, Incyte announced the end of solid state cancer drug research and development business. Jakafi in 2011 for the first time approved for the treatment of bone marrow fibrosis, 2014 polycythemia vera indications approved, the rare blood cancer treatment in the field of solid market position.

In November 2016, the potential competitor - momelotinib (Gilead) phase III clinical indications for multiple sclerosis, Incyte, which means that the market space is still considerable.

14, Venclexta

Venclexta, developed by AbbVie and Roche, is the world's first BCL-2 inhibitor, which was launched in the United States in 2016 for the treatment of chronic lymphocytic leukemia caused by mutations in the gene. The drug is currently priced at $110 thousand a year, the future may be Roche combined with rituximab for chronic lymphocytic leukemia.

Venclexta future competitors include new medicine lenalidomide, Ai Bowei's own Imbruvica, Zydelig and Gilead listing (idelalisib). Aibo Wei CEO Richard Gonzalez recently revealed that Venclexta is likely to help promote the sales of the Imbrvica, or the latter have a positive effect, the combination of the two may become chronic lymphocytic leukemia treated with the most effective solution.

15, Rituxan

Rituximab (Rituxan) has been on the market for 20 years, is currently Roche's top third sales. So far, the drug still maintain a certain growth rate, the first half of 2016, an increase of 6%.

However, the biological drugs challenge will usher in the rituximab at the end of 2017, 2022 sales will lose $4 billion 500 million. Celltrion company led the administration of biological medicine research and development similar to the European medicines, which in October 2015 the Bureau (EMA) submitted a listing application of rituximab like creature medicine CT-P10; Novartis Sandoz generics unit (Sandoz) developed by the biological drug like version submitted a listing application to the EU in May 2016; in December 2016, Senofi (Sanofi) a cooperate with JHL Biotech Corp, the former $236 million business strategy promotes JHL similar to the drug rituximab biological talent shows itself.

色多多下载官方版_色多多app最新版下载_色多多深夜福利免费观看_色多多网站入口官方版下载